TKI Monotherapy Data in Non–Clear Cell RCC
Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.
EP: 1.First-Line Treatments for Advanced Clear Cell RCC
EP: 2.Long-Term Follow-Up from CheckMate 214 in Advanced RCC
EP: 3.CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC
EP: 4.Recent Subgroup Analyses from the CLEAR study in Advanced RCC
EP: 5.LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis
EP: 6.Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC
EP: 7.CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC
EP: 8.Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC
EP: 9.LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research
EP: 10.Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC
EP: 11.CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC
EP: 12.Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC
EP: 13.Clinical Insights on Belzutifan in Advanced RCC
EP: 14.Overview of Non–Clear Cell RCC
Now Viewing
EP: 15.TKI Monotherapy Data in Non–Clear Cell RCC
EP: 16.KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC
EP: 17.Nivolumab Plus Cabozantinib in Non–Clear Cell RCC
EP: 18.Future Perspectives and Unmet Needs in Renal Cell Carcinoma
Related Videos
Related Content
